Remdesivir (Veklury®)

Covered: Veklury (remdesivir) is authorized for a single 3‑day IV course to treat mild-to-moderate COVID‑19 in patients at high risk for progression (FDA ≥12 years and compendial use <12 years); excluded are patients <3.5 kg, without a positive SARS‑CoV‑2 test, not high‑risk, with severe disease, receiving non‑IV therapy, or needing >1 three‑day course. Key requirements: documented positive SARS‑CoV‑2 test, weight ≥3.5 kg, documentation of high‑risk status and age, and specified IV dosing (≥40 kg: 200 mg IV day 1 then 100 mg IV days 2–3; 3.5–<40 kg: 5 mg/kg IV day 1 then 2.5 mg/kg IV days 2–3).

"Approval duration: 3 days (one treatment course)."

Sign up to see full coverage criteria, indications, and limitations.